Acadian Asset Management
SLNO

Acadian Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Acadian Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,523
Closed -$76K – 2119
2024
Q3 		$76K Buy
+1,523
New +$72.9K ﹤0.01% 1685

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Acadian Asset Management's SLNO Position: Q4 2024 in Review

Acadian Asset Management sold out of Soleno Therapeutics (SLNO) in Q4 2024, closing a stake of 1,523 shares — an estimated $76K sold.

Acadian Asset Management first reported a position in SLNO in Q3 2024 and held it in 1 quarter. The position peaked at $76K in Q3 2024. 166 funds tracked by Wall St. Rank hold SLNO as of Q4 2024.

  • Acadian Asset Management reported no remaining Soleno Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 1,523 Soleno Therapeutics shares in Q4 2024, an estimated $76K.
  • Acadian Asset Management first reported a position in Soleno Therapeutics in Q3 2024 and held it in 1 quarter.
  • Acadian Asset Management's Soleno Therapeutics position peaked at $76K in Q3 2024.
  • 166 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.